{"groups":[{"description":"azacitidine: Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.\n\nlenalidomide: Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.","id":"FG000","title":"Lenalidomide and Azacitidine"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"37"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"Azacitidine 75mg/Lenalidomide 5mg-14 Day"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"Azacitidine 75mg/Lenalidomide 5mg-21 Day"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"Azacitidine 75mg/Lenalidomide 10mg-14day"},{"achievements":[{"groupId":"FG000","numSubjects":"37"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}